GSK2606414
GSK2606414[edit | edit source]
GSK2606414 is a potent and selective inhibitor of the protein kinase PERK (PKR-like endoplasmic reticulum kinase), which is involved in the unfolded protein response (UPR) pathway. This compound has been studied for its potential therapeutic applications in diseases characterized by endoplasmic reticulum stress, such as neurodegenerative diseases and certain types of cancer.
Mechanism of Action[edit | edit source]
GSK2606414 functions by inhibiting the activity of PERK, a key sensor of the unfolded protein response. Under conditions of endoplasmic reticulum stress, PERK is activated and phosphorylates the eukaryotic initiation factor 2 alpha (eIF2_), leading to a reduction in general protein synthesis and an increase in the translation of specific stress-related proteins. By inhibiting PERK, GSK2606414 prevents the phosphorylation of eIF2_, thereby modulating the cellular response to stress.
Therapeutic Potential[edit | edit source]
Neurodegenerative Diseases[edit | edit source]
In neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), the accumulation of misfolded proteins can lead to chronic ER stress and activation of the UPR. GSK2606414 has been investigated for its ability to alleviate ER stress and improve cell survival in models of these diseases.
Cancer[edit | edit source]
In certain types of cancer, the UPR is hijacked to support tumor growth and survival under stressful conditions such as hypoxia and nutrient deprivation. By inhibiting PERK, GSK2606414 may disrupt the adaptive UPR in cancer cells, leading to increased sensitivity to stress and potential cell death. This makes it a candidate for combination therapy with other anticancer agents.
Challenges and Considerations[edit | edit source]
While GSK2606414 shows promise in preclinical studies, there are challenges associated with its use. The inhibition of PERK can have widespread effects on cellular homeostasis, and careful consideration of dosing and potential side effects is necessary. Further research is needed to fully understand the implications of PERK inhibition in different disease contexts.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
